<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000518652"><TermName>17-AAG</TermName><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. It is made from an antibiotic called geldanamycin. 17-AAG helps cause the breakdown of certain proteins in the cell, and may kill cancer cells. It is a type of antineoplastic antibiotic and a type of HSP90 inhibitor. Also called 17-N-allylamino-17-demethoxygeldanamycin and tanespimycin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>17-AAG</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Está elaborado con un antibiótico que se llama geldanamicina. 17-AAG ayuda a descomponer ciertas proteínas de la célula y podría destruir células cancerosas. Es un tipo de antibiótico antineoplásico y un tipo de inhibidor de la HSP90. También se llama 17-N-alilamino-17-demetoxigeldanamicina y tanespimicina.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-11-13</DateFirstPublished><DateLastModified>2008-10-15</DateLastModified></GlossaryTerm>
